Drugs / BNT116
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05142189 | Jun 2022 → Feb 2030 expected | non-small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05557591 | Apr 2023 → Jan 2028 expected | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05557591 ↗ |
| Modality | Vaccine | “cancer vaccine BNT116” NCT05557591 ↗ |
| Route | Intravenous | “Intravenous injection” NCT05142189 ↗ |